Q2 2025 BioMarin Pharmaceutical Inc Earnings Call Transcript
Key Points
- BioMarin Pharmaceutical Inc (BMRN) achieved double-digit year-over-year revenue growth and significant profitability expansion in Q2 2025.
- The company successfully completed the acquisition of Inozyme, broadening its enzyme therapies portfolio.
- BMN 333, a long-acting therapy for achondroplasia, achieved its target profile, with plans to advance to a Phase 2/3 study.
- VOXZOGO revenue increased 20% year over year, driven by global expansion and strong treatment adherence.
- BioMarin raised its full-year 2025 guidance for total revenues, non-GAAP operating margin, and earnings per share due to strong performance.
- Non-GAAP SG&A expenses increased year over year due to investments in enterprise resource planning and strategic initiatives.
- Higher operating expenses are expected in the second half of 2025, which may decrease operating margins compared to the first half.
- The company anticipates lower earnings per share in the second half of the year due to increased business unit investments.
- Revenue from VOXZOGO is expected to be weighted towards Q4, with potential fluctuations due to order timing outside the US.
- The company is still awaiting regulatory alignment for BMN 333 outside the US, which could impact the timeline for its development.
Good afternoon. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceutical second quarter 2025 conference call. Today's conference is being recorded. (Operator Instructions)
At this time while I turn the conference over to Traci McCarty, Investor Relations at BioMarin. Please go ahead.
Thank you, operator. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market, and developments by competitors, and those factors detailed in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
